Restricting Access to Medicaid Populations

January 15, 2005
Volume 11, Issue 1 SP

Dear Reader,

The American Journal of Managed Care

In 2004, published more theme and special issues than ever before. That trend will likely continue in 2005, and you're holding the first evidence of this development.

The formulation and adoption of preferred drug lists (PDLs) by state and federal agencies is a fairly recent development. These PDLs have arisen both as a means to control costs and as response to changes in the Medicare drug law. Given the continuing evolution of these programs, and the further changes to the Medicare drug program set to take effect in 2006, it is important to examine these programs and their consequences in detail. That task is made difficult, however, due to the paucity of research available in this area. This collection of papers may begin to remedy that problem.

These 5 papers and the introduction to them should help sketch the landscape of drug access restrictions at the beginning of 2005, and will also hopefully lay out the areas where additional research is needed. As ever, we welcome your feedback on this special issue, and look forward to publishing additional theme and special issues as the year continues.

The Editors

Funding for this Special Issue was provided by Pfizer Inc, New York, NY.